ImmunityBio Advances Pipeline with Phase 2 Lymphoma Trial

ImmunityBio has initiated a Phase 2 clinical study for a chemotherapy-free treatment of indolent B-cell non-Hodgkin lymphoma. The trial, which commenced on February 2, 2026, represents a significant expansion of the biotechnology firm's development pipeline for difficult-to-treat cancers.

Designated ResQ215B, this clinical investigation will evaluate a unique combination of three agents. The regimen includes ImmunityBio’s CD19-targeted natural killer cell therapy (CD19 t-haNK), the already-approved IL-15 superagonist ANKTIVA®, and the monoclonal antibody Rituximab. This strategy marks a distinct departure from conventional CAR-T cell therapies, as it eliminates the need for lymphodepleting chemotherapy and is designed for outpatient administration.

Eligibility for the study extends to patients diagnosed with Waldenström's macroglobulinemia and other specified lymphoma subtypes. The therapeutic rationale focuses on engaging multiple signaling pathways to enhance the body's innate immune response against cancer cells. Preliminary data from earlier studies involving heavily pre-treated patients had indicated promising potential for this approach.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Building on Recent Regulatory Momentum

The launch of the ResQ215B study follows a series of important regulatory developments for the company in the preceding month. January 2026 saw ImmunityBio disclose that it was engaged in advanced discussions with the U.S. Food and Drug Administration (FDA) regarding a potential resubmission for ANKTIVA in a specific form of bladder cancer.

Concurrently, the Saudi Arabian health authority granted an accelerated approval for Anktiva in combination with BCG for the treatment of a bladder cancer variant. These clinical and regulatory milestones are described as central components of the company's strategic roadmap.

The commencement of this new lymphoma trial further broadens ImmunityBio's active research and development program, which is concentrated on addressing oncology indications with high unmet medical need.